The antitumor activity of a mitomycin derivative, 7-N-[2-[[2-(γ-glutamylamino)ethyl]dithio]ethyl]mitomycin C (KW-2149), was evaluated in murine and human tumor models, including a mitomycin C (MMC)-resistant tumor in vitro and in vivo. KW-2149 showed a profound effect against i.p. inoculated P388 leukemia on both a single and an intermittent administration schedule. Against s.c. implanted colon adenocarcinoma 38 (colon 38), KW-2149 was as effective as MMC in ILS% and in tumor growth inhibition on a single-administration schedule. Both compounds were similarly effective when an intermittent schedule was used. KW-2149 showed activity against human tumor xenografts and was effective in two of four non-small-cell lung carcinomas but was not effective against three gastric adenocarcinomas on the singleadministration regimen. The activity of KW-2149 against gastric adenocarcinoma was inferior to that of MMC on a single-administration schedule. However, the antitumor activity of KW-2149 was higher on an intermittent schedule than on a single-administration regimen. The antitumor activity of KW-2149 against human tumor xenografts was similar to that of MMC on an intermittent schedule, and the former drug was effective against both gastric adenocarcinomas and both non-small-cell lung carcinomas. KW-2149 was more effective than MMC against a subline of P388 leukemia that is resistant to MMC in vitro as well as in vivo.
This is a preview of subscription content, log in to check access.
Buy single article
Instant access to the full article PDF.
Price includes VAT for USA
Subscribe to journal
Immediate online access to all issues from 2019. Subscription will auto renew annually.
This is the net price. Taxes to be calculated in checkout.
Cosulich DB, Patric JB, Williams RP (1960) Reaction products of mitomycin and porfiromycin. United States Patent 321440 (CI, 260-319), October 26, 1959 (Chemical abstract 64, P533c)
Geran RL, Greenberg NH, MacDonald MM, Schumacher AM, Abbott BJ (1972) Protocol against animal tumor and other biological system. Cancer Chemother Rep 3: 1
Imai R, Ashizawa T, Urakawa C, Morimoto M, Nakamura N (1980) Antitumor activity of 7-N-phenyl derivatives of mitomycin C in leukemia P388 system. Gann 71: 560
Inaba M, Fujikura R, Sakurai Y (1979) Comparative study on in vivo development of resistance to various classes of antitumor agents in P388 leukemia. Gann 70: 607
Inaba M, Tashiro T, Kobayashi T, Sakurai Y, Maruo K, Ohnishi Y, Ueyama Y, Nomura T (1988) Responsiveness of human gastric tumors implanted in nude mice to clinically equivalent doses of various anticancer agents. Jpn J Cancer Res 79: 517
Iyengar BS, Sami SM, Remers WA, Bradner WT, Schurig JE (1983) Mitomycin C and porfiromycin analogues with substituted ethylamine at position 7. J Med Chem 26: 16
Kono M, Saito Y, Kasai M, Sato A, Shirahata K, Morimoto M, Ashizawa T (1989) Synthesis and antitumor activity of 7-N-[2-[2-(γ-l-glutamylamino)ethyl]dithio]ethyl]mitomycin C. Chem Pharm Bull 37: 1128
Morimoto M, Ashizawa T, Akinaga S, Azuma M, Kono K, Saito T, Sato A, Kasai K (1988) Antitumor activity of 7-N-[2-[2-(γ-l-glutamylamino)ethyl]dithio]ethyl]mitomycin C. Proc Am Assoc Cancer Res 29: 266
Morimoto M, Ashizawa T, Ohno H, Azuma M, Kobayashi E, Okabe M, Gomi K, Kono M, Saitoh Y, Kanda Y, Arai H, Sato A, Kasai M, Tsuruo T (1990) Antitumor activity of 7-N-[2-[2-(γ-l-glutamylamino)ethyl]dithio]ethyl]mitomycin C. Cancer Res (in press)
Sami SM, Iyengar BS, Tarnow SE, Remers WA, Bradner WT, Schurig JE (1983) Mitomycin C analogs with secondary amine at position 7. J Med Chem 26: 1453
Tashiro T, Inaba M, Kobayashi T, Sakurai Y, Maruo M, Ohnishi Y, Ueyama Y, Nomura T (1989) Responsiveness of human lung cancer/nude mouse to antitumor agents in a model using clinically equivalent doses. Cancer Chemother Pharmacol 24: 187
Tomasz M, Lipman R, Chowday D, Rawlack J, Verdine GL, Nakanishi K (1987) Isolation and structure of a covalent cross-link adduct between mitomycin C and DNA. Science 235: 1204
Tsuruo T, Iida H, Tsukagashi S, Sakurai Y (1981) Overcoming of vincristine resistance in P388 leukemia in vivo and in vitro through enhanced cytotoxicity of vincristine and vinblastine by verapamil. Cancer Res 41: 1967
Usubichi I, Sobajima Y, Hongo T, Kawaguchi T, Sugayashi M, Matsui M, Wakagi S, Uzu K (1967) Antitumor studies on mitomycin derivatives: effect on Hirosaki ascites sarcoma. Gann 58: 307
Watanabe M, Kumeshima N, Nakajima S, Tsuruo T (1988) MX 2, a morpholine anthracycline, as a new antitumor agent against drugsensitive and multidrug-resistant human and murine tumor cells. Cancer Res 48: 6653
Wilson JKV, Long BH, Chakrabarty S, Brattain, DE, Brattain MG (1985) Effect of BMY25282 a mitomycin C analogue in mitomycin C-resistant human colon cancer cells. Cancer Res 45: 5281
About this article
Cite this article
Tsuruo, T., Sudo, Y., Asami, N. et al. Antitumor activity of a derivative of mitomycin, 7-N-[2-[[2-(γ-l-glutamylamino)ethyl]dithio]ethyl]mitomycin C (KW-2149), against murine and human tumors and a mitomycin C-resistant tumor in vitro and in vivo. Cancer Chemother. Pharmacol. 27, 89–93 (1990). https://doi.org/10.1007/BF00689089
- Antitumor Activity
- Human Tumor
- Lung Carcinoma